Results 1 to 10 of about 1,036,044 (316)

Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy

open access: yesHaematologica, 2022
CD19-specific chimeric antigen receptor (CD19-CAR) T-cell therapies mediate durable responses in late-stage B-cell malignancies, but can be complicated by a potentially severe immune effector cell-associated neurotoxicity syndrome (ICANS). Despite broad
Susanna Carolina Berger   +16 more
doaj   +1 more source

Spontaneous Complete Remission of Acute Myeloid Leukemia in the Absence of Disease-Modifying Therapy following Severe Pulmonary Involvement by Coronavirus Infectious Disease-19

open access: yesCase Reports in Hematology, 2022
Coronavirus infectious disease-19 (COVID-19) usually alters the innate and adaptive immune setting by excessive production of proinflammatory cytokines, leading to a deviation in the natural course of simultaneous malignant disease.
Maryam Barkhordar   +5 more
doaj   +1 more source

Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosis

open access: yesScientific Reports, 2021
Targeting the interaction between leukemic cells and the microenvironment is an appealing approach to enhance the therapeutic efficacy in acute myeloid leukemia (AML).
Meike Farber   +8 more
doaj   +1 more source

Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation

open access: yesHaematologica, 2021
Anti-T-cell lymphocyte globulin (ATLG) and posttransplant cyclophosphamide (PTCy) are now widely used strategies to prevent graft-versus-host disease (GVHD) after allogeneic stem cell transplantation.
Radwan Massoud   +8 more
doaj   +1 more source

Risk assessment for newly diagnosed, fit and young patients with Multiple Myeloma, in the era of novel treatment modalities: Are there any additional factors to be under consideration?

open access: yesHematology, Transfusion and Cell Therapy, 2022
Objective: Multiple myeloma (MM) is considered a disease of elderlies however, 35-40% of newly diagnosed MM (NDMM) patients (pts) are ≤60 years (ys) old.
Panayotis Kaloyannidis   +6 more
doaj   +1 more source

The genomic analysis brings a new piece to the molecular jigsaw of idiopathic erythrocytosis

open access: yesExperimental Hematology & Oncology, 2022
Erythrocytosis is a clinical condition characterized by increased red cell mass, hemoglobin, and hematocrit values. A significant fraction of patients is described as having idiopathic erythrocytosis.
Antonella Zagaria   +15 more
doaj   +1 more source

Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis

open access: yesHaematologica, 2021
High-dose chemotherapy and autologous stem-cell transplant (HDC/ASCT) is standard treatment for chemosensitive relapsed classical Hodgkin lymphoma, although outcomes of high-risk relapse (HRR) patients remain suboptimal.
Yago Nieto   +32 more
doaj   +1 more source

Nanopore sequencing approach for immunoglobulin gene analysis in chronic lymphocytic leukemia

open access: yesScientific Reports, 2021
The evaluation of the somatic hypermutation of the clonotypic immunoglobulin heavy variable gene has become essential in the therapeutic management in chronic lymphocytic leukemia patients.
Crescenzio Francesco Minervini   +15 more
doaj   +1 more source

Harnessing the power of cell transplantation to target respiratory dysfunction following spinal cord injury. [PDF]

open access: yes, 2017
The therapeutic benefit of cell transplantation has been assessed in a host of central nervous system (CNS) diseases, including disorders of the spinal cord such as traumatic spinal cord injury (SCI).
Charsar, Brittany A.   +2 more
core   +2 more sources

Home - About - Disclaimer - Privacy